In this phase 1/2 study exploring the clinical efficacy of a therapeutic cancer vaccine with peptides derived from PD-L1 and PD-L2 in untreated CLL patients with unmutated IgHV, we did not see any responses according to the iwCLL response criteria (3). Here, PDCD1LG2 is linked to B-cell chronic lymphocytic leukemia.